{"filings":[{"id":95547,"accession_number":"0001104659-26-049434","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott adds Kevin Conroy to board; shareholders approve 2026 Incentive Stock Program","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Conroy appointed to Abbott's Board of Directors effective April 24, 2026.","Shareholders approved the 2026 Incentive Stock Program authorizing up to 140 million shares, replacing the 2017 plan.","Board size increased from 12 to 13 directors via bylaw amendment effective April 24, 2026.","The 2026 Program has a ten-year term and permits stock options, RSUs, performance awards, and other equity grants.","All director nominees were elected; Ernst & Young ratified as independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95546,"accession_number":"0001104659-26-044892","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abbott reaches settlement in shareholder derivative suit over infant formula; governance reforms, up to $15.85M fees","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.","Abbott to adopt corporate governance reforms; no admission of wrongdoing.","Lead plaintiffs' counsel seeks up to $15.85M in fees/expenses and service awards up to $15,000 each.","Court approval hearing set for June 4, 2026; shareholder objections due by May 18, 2026.","Dismissal with prejudice of all claims; governance enhancements to improve compliance oversight."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95545,"accession_number":"0001628280-26-025365","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).","Q1 sales $11.16B, reported +7.8%, comparable +3.7%.","Completed Exact Sciences acquisition March 23; adds $0.20 dilution to FY EPS guidance.","FY2026 guidance: comparable sales growth 6.5%-7.5%; adjusted EPS $5.38-$5.58.","Medical Devices +8.5% comparable; Diabetes CGM +7.6% comparable; Nutrition -7.7% comparable."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":11164000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108695,"accession_number":"0001104659-26-033079","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.","Exact Sciences last trading day was March 20, 2026; shares converted to $105 cash.","Deal adds Cologuard, Oncotype DX, Oncodetect, Cancerguard cancer screening diagnostics.","Abbott becomes leader in $60B U.S. cancer screening and precision oncology diagnostics market.","Acquisition adds growth vertical to Abbott's high-single-digit growth expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108694,"accession_number":"0001104659-26-025240","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Abbott completes $20B senior notes offering to fund Exact Sciences acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.","Net proceeds to fund Exact Sciences acquisition (announced Nov 2025), repay Exact Sciences debt, pay fees, and general purposes.","If Exact Sciences acquisition not consummated by Feb 17, 2027, Abbott must redeem notes at 101% plus accrued interest.","Underwriters include Morgan Stanley, Barclays, BofA Securities, J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108693,"accession_number":"0001104659-26-020509","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.","Net proceeds will fund the Exact Sciences acquisition, repay Exact Sciences debt, and for general corporate purposes.","Underwriters include Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities.","Closing expected on March 9, 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108692,"accession_number":"0001104659-26-018167","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Abbott reduces board size from 13 to 12 directors effective April 24, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board of Directors amended Article III, Section 2 of By-Laws on February 20, 2026.","Board size reduced from 13 to 12 persons, effective April 24, 2026.","Amended By-Laws filed as Exhibit 3.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108691,"accession_number":"0001628280-26-002982","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).","FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).","FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).","Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.","Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System."],"consensus_eps_estimate":null,"consensus_eps_actual":3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":44328000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125137,"accession_number":"0001104659-25-120657","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Abbott names Nita Ahuja to Board of Directors; board expands to 13 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nita Ahuja, M.D. appointed to Abbott’s Board of Directors effective December 12, 2025.","Board size increased from 12 to 13 members via bylaw amendment on the same date.","Amended and restated by-laws filed as Exhibit 99.1; no additional details on Dr. Ahuja provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125136,"accession_number":"0001104659-25-114995","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.04","9.01"],"status":"ready","headline":"Abbott blackout period for retirement plan Dec 24 to Jan 11 due to admin changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Blackout begins Dec 24, 2025 at 12pm CST, ends week of Jan 11, 2026.","Plans changing recordkeepers, trustees (U.S. Plan), and custodian (P.R. Plan).","Participants cannot change contributions, direct investments, take loans, or request distributions.","Directors and executive officers prohibited from trading Abbott equity during blackout per Regulation BTR.","No financial impact or change to company operations; routine administrative transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125135,"accession_number":"0001104659-25-114422","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.","Exact Sciences 2025 revenue >$3B with high-teens organic growth; adds cancer diagnostics vertical.","Close expected Q2 2026, subject to Exact Sciences shareholder vote and regulatory approvals (incl. HSR).","Immediately accretive to Abbott's revenue growth (+50bps Abbott, +300bps Diagnostics) and gross margin (+100bps).","Financing via cash and up to $20B bridge loan from Morgan Stanley; initial 2026 debt/EBITDA ~2.7x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125134,"accession_number":"0001628280-25-045049","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).","Medical Devices up 14.8% reported, led by Diabetes Care CGM sales of $2.0B (+20.5% reported, +17.2% organic).","FY2025 organic sales guidance reaffirmed at 7.5-8.0% ex-COVID; adjusted EPS narrowed to $5.12-$5.18 (midpoint double-digit growth).","Adjusted operating margin improved 40bps to 23.0% of sales."],"consensus_eps_estimate":null,"consensus_eps_actual":2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":32869000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141846,"accession_number":"0001628280-25-035135","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.","Total reported sales $11.14B, +7.4% reported, +6.9% organic, +7.5% ex-COVID tests.","Medical Devices organic growth 12.2%; Diabetes Care CGM sales $1.9B, +19.6% organic.","Full-year 2025 guidance: organic sales growth ex-COVID 7.5%-8.0%; adjusted EPS $5.10-$5.20.","Q3 2025 adjusted diluted EPS guidance $1.28-$1.32; adjusted operating margin ~23.5% for FY."],"consensus_eps_estimate":null,"consensus_eps_actual":1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":21500000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159784,"accession_number":"0001104659-25-043508","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott General Counsel Hubert L. Allen to retire after transition period","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hubert L. Allen, EVP, General Counsel and Secretary, notified Abbott on April 25, 2025 of his planned retirement.","Allen will remain with the company through a transition period; no replacement has been named.","Departure is described as retirement, not termination; no severance or change-in-control triggered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159783,"accession_number":"0001104659-25-040201","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Abbott annual meeting results: all directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Nancy McKinstry received 1.12B for vs 243.9M against (82%).","Ratification of Ernst & Young as independent auditor passed with 1.50B votes for, 36.6M against.","Advisory say-on-pay vote approved with 89.90% of votes cast in favor (1.22B for, 130.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159782,"accession_number":"0001628280-25-017924","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).","Reported revenue $10.36B (+4.0%), organic sales +6.9% (+8.3% ex-COVID testing).","Medical Devices sales +9.9% reported (+12.6% organic); FreeStyle Libre revenue $1.7B.","Full-year 2025 adjusted EPS guidance reaffirmed: $5.05-$5.25; Q2 adj. EPS $1.23-$1.27.","Volt PFA System received CE Mark; TECTONIC IVL pivotal trial initiated in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":10358000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178160,"accession_number":"0001628280-25-002092","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.","Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).","Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.","Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.","FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":7.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":41950000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194821,"accession_number":"0001104659-24-119717","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott extends change-in-control agreements for NEOs through Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreements previously set to expire Dec 31, 2024, now extended to Dec 31, 2026.","Notification given to named executive officers on November 12, 2024.","Extension automatically continues term through second anniversary of original expiration date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194820,"accession_number":"0001628280-24-042893","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.","GAAP diluted EPS $0.94; adjusted diluted EPS $1.21; FY 2024 adj. EPS guidance raised to $4.64-$4.70.","FreeStyle Libre CGM sales >$1.6B (+20.7% organic); new $7B share repurchase authorized; quarterly dividend $0.55.","Partnered with Medtronic to connect CGM with insulin devices; launched OTC Lingo CGM in U.S.; completed VOLT-AF trial enrollment.","Nutrition organic +3.4% (Adult +9.1%); Diagnostics organic ex-COVID +3.3% (Core Lab +4.5%); Established Pharma organic +7.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":30976000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211113,"accession_number":"0001628280-24-032182","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).","FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.","Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).","New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).","Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase."],"consensus_eps_estimate":null,"consensus_eps_actual":1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":20341000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229641,"accession_number":"0001104659-24-055724","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Abbott EVP Finance Robert Funck Jr. to retire July 1, 2024 after 36 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Funck Jr., Executive Vice President, Finance, plans to retire effective July 1, 2024.","Funck has served at Abbott Laboratories for 36 years.","No successor has been named; Philip Boudreau remains Senior VP, Finance and CFO.","Departure is a planned retirement, not a termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229640,"accession_number":"0001104659-24-054016","cik":1800,"company_name":"ABBOTT LABORATORIES","ticker":"ABT","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":[],"status":"ready","headline":"Abbott annual meeting results elect board, ratify auditor, approve executive compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 board nominees elected; Nancy McKinstry received ~242.6M against votes, John G. Stratton ~347.3M against.","Ernst & Young LLP ratified as auditor with 1.492B votes for, 42.9M against.","Advisory say-on-pay approved with 89.10% support (1.212B for, 144.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":149238481388.2783,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}